AUPH

Aurinia Pharmaceuticals Inc.

Fundamental data last updated:October 28, 2026

We may earn a commission from partner links. This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate.

company profile

SECTOR

Healthcare

industry

Biotechnology

Exchange

NASDAQ

County of HQ

CA

Next Earnings Date

11/03/2026

Business Summary

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

 


Analyze AUPH on TradingView

VALUATION

P/E

7.22

Market Cap ($M USD)

$2.27B

Forward P/E

17.97

PEG

0.34

PRICE TO SALES

7.28

PRICE TO BOOK

3.60

EV / EBITDA

11.41

5-Year Average P/E

Free Cash Flow Yield

7.66%

DCF Value

$-46.28

Graham Number

$16.03

Price to FCF

13.06

EV to FCF

12.37

Earnings Yield

14.18%

FCF Yield

7.66%

DIVIDEND

Yield

0.00%

Annual Payout

$0.00

Payout Ratio

0.00%

Consecutive Years of Dividend Growth

5-Year Dividend Growth Rate

Financial Health & Profitability

Earnings Per Share

$2.41

Next Year EPS Growth Estimate

$0.95

Next Year Revenue Growth Estimate

$330.27M

Return on Equity (ROE)

59.00%

FREE CASH FLOW

Operating Margin

48.39%

Debt-to-Equity

0.10

Piotroski F-Score

6

Altman Z-Score

8.33

Return on Invested Capital (ROIC)

21.27%

Current Ratio

5.42

Quick Ratio

4.97

Net Debt to EBITDA

-0.63

Interest Coverage

17.79

Gross Profit margin

90.36%

FCF PER SHARE

$1.33

REVENUE PER SHARE

$2.39

Analyze AUPH on TradingView

Gainseekers Quantitative Analysis

Summary

Aurinia Pharmaceuticals Inc. presents a perplexing valuation scenario. Despite a robust Altman Z-score of 8.29 indicating financial stability, the stock’s market price has been trading below its DCF value, suggesting potential mispricing. The Forward P/E of 8.84 and an impressive Earnings Yield of 14.79% highlight its attractiveness for growth at a reasonable price. However, the Graham Number of 14.74 suggests the stock might be slightly overvalued at its snapshot price. Overall, the market seems to underestimate its growth potential, given the strong fundamentals.

AI Exposure / Tech Reliance

Operating within the biotechnology sector, Aurinia Pharmaceuticals is well-positioned to leverage AI advancements in drug discovery and personalized medicine. The industry's inherent focus on innovation aligns with technological shifts, potentially enhancing R&D efficiency. This adaptability could drive long-term growth and competitive advantage.

The Bull Case

For the discerning GARP investor, Aurinia shines with its stellar ROIC of 19.53%, showcasing efficient capital allocation. The FCF Yield of 8.45% and a Piotroski F-Score of 6 indicate solid financial health and operational efficiency. Its operating margin of 41.73% underscores strong pricing power, suggesting the company can effectively convert sales into profits. These metrics paint a picture of a company with significant upside potential and a compelling value proposition.

The Bear Case

Despite its strengths, Aurinia faces structural risks. The Price/Book ratio of 3.55 and Price/Sales of 6.57 suggest a premium valuation, potentially limiting upside. Trading close to its 52-week high, the stock appears technically overextended, raising concerns about short-term volatility. Additionally, the negative PEG Forward ratio hints at potential growth challenges, warranting caution for investors seeking consistent growth trajectories.

Market Sentiment & Smart Money

Short Interest %

Analyst Consensus

Buy

Average Analyst Price Target

$16.00

Institutional Ownership %

1-Year Beta

1.41

Insider Buying % (6 Mo)

Distance to 52-Week High

13.00%

Distance to 52-Week Low

30.23%

EARNINGS SURPRISE %

16.67%

50-DAY SMA

$16.37

200-DAY SMA

$15.60

⚠️ Financial Disclaimer:
This content is for informational purposes only and is not financial advice. Information may be delayed or inaccurate. We may earn a commission from partner links.